Due to differences in molecular characteristics of breast cancer sub-types, the use of biomarkers, histologic grade, HER2 expression, hormone receptor, and multigene panels have now been incorporated into the conventional TNM staging (6). The gene discussed is ERBB2; the disease is breast carcinoma.